PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 84 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2013. The put-call ratio across all filers is 4.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $736,000 | -26.2% | 193,584 | -1.2% | 0.00% | 0.0% |
| Q4 2019 | $997,000 | +41.4% | 195,884 | +40.4% | 0.00% | 0.0% |
| Q3 2019 | $705,000 | -3.0% | 139,500 | +18.3% | 0.00% | 0.0% |
| Q2 2019 | $727,000 | +21.2% | 117,900 | -8.9% | 0.00% | 0.0% |
| Q1 2019 | $600,000 | +10.5% | 129,400 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $543,000 | -40.0% | 129,400 | -10.4% | 0.00% | 0.0% |
| Q3 2018 | $905,000 | -20.1% | 144,415 | +2.6% | 0.00% | -50.0% |
| Q2 2018 | $1,132,000 | -11.9% | 140,800 | -18.2% | 0.00% | 0.0% |
| Q1 2018 | $1,285,000 | +25.4% | 172,200 | 0.0% | 0.00% | +100.0% |
| Q4 2017 | $1,025,000 | -19.1% | 172,200 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $1,267,000 | +8.4% | 172,200 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,169,000 | -28.1% | 172,200 | 0.0% | 0.00% | -33.3% |
| Q1 2017 | $1,626,000 | +4.7% | 172,200 | -4.2% | 0.00% | 0.0% |
| Q4 2016 | $1,553,000 | +29.8% | 179,700 | -4.9% | 0.00% | +50.0% |
| Q3 2016 | $1,196,000 | +40.4% | 188,900 | -6.4% | 0.00% | +100.0% |
| Q2 2016 | $852,000 | -6.1% | 201,800 | -3.0% | 0.00% | 0.0% |
| Q1 2016 | $907,000 | -32.9% | 208,100 | -5.7% | 0.00% | -50.0% |
| Q4 2015 | $1,352,000 | +7.1% | 220,600 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $1,262,000 | -23.3% | 220,600 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $1,646,000 | -11.8% | 220,600 | -26.6% | 0.00% | -33.3% |
| Q1 2015 | $1,867,000 | 0.0% | 300,642 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,867,000 | +19.7% | 300,642 | 0.0% | 0.00% | +50.0% |
| Q3 2014 | $1,560,000 | +24.5% | 300,642 | +3.4% | 0.00% | 0.0% |
| Q2 2014 | $1,253,000 | +10.6% | 290,646 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $1,133,000 | -26.5% | 290,646 | +7.2% | 0.00% | 0.0% |
| Q4 2013 | $1,542,000 | +37.8% | 271,062 | +21.8% | 0.00% | 0.0% |
| Q3 2013 | $1,119,000 | +12.8% | 222,515 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $992,000 | – | 222,515 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |